FindTrial
Sign In

Clinical study on prophylactic infusin of CAR-T cells in preventing relapse of acute lymphoblatic leuekmia after allogeneic stem cell transplantation

Effect of prophylactic infusin of CAR-T cells in preventing relapse of acute lymphoblatic leuekmia after allogeneic stem cell transplantation: A phase I, non-blind, non-control,single-central study

Status
Unknown
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015353
Enrollment
Unknown
Registered
2022-03-26
Start date
2018-03-12
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell acute lymphoblastic leukemia

Interventions

Case series:CAR-T cell

Sponsors

Department of hematology, Xinqiao hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients with the B-cell acute lymphoblast leukemia with molecular relapse after allogeneic hematopoietic stem cell transplantation with CD19 expression; 2. no GVHD, Male or Femal with any ages; 3. The estimated survival is over three months; 4. ECOG performance status of <= 2 at study entry; 5. The important organs are function,such as heart and brain.

Exclusion criteria

Exclusion criteria: 1. The uncontroled infection. HBV and HCV are positive; 2. The patients received any cell immunotherapy in the past.

Design outcomes

Primary

MeasureTime frame
One-year disease-free survival;—

Secondary

MeasureTime frame
One-year disease-free overalsurvival;GVHD;Infection;—

Countries

China

Contacts

Public ContactZhang Cheng

Department of hematology, Xinqiao hospital, Army Medical University

chzhang2014@163.com+86 23 687774209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026